It's Tuesday, which means MD Biosciences is providing coverage of the latest fascinating and innovative discoveries happening all over the world across a wide variety of disciplinary areas. This week's blog is compiling posts from science journals including Nature Medicine, Nature Genetics, Medical Xpress, PM360, ScienceDaily and Science. Skim the titles below to catch up on what is happening and follow the links to read more about something that catches your eye!
It's Tuesday and we're back with covering the latest fascinating and innovative discoveries happening all over the world across a wide variety of disciplinary area. This week's blog is providing up-to-date news coverage compiling posts from science journals including Advanced Materials, Cell, EurekAlert, ScienceDaily, Proceedings of the National Academy of Sciences, News Medical and Nature Biomedical Engineering. Skim the titles below to catch up on what is happening and follow the links to read more about something that catches your eye!
MD Biosciences providing up-to-date news coverage compiling posts from science journals including Cancer Research, Sci News, Nature Genetics, British Journal of Pharmacology and Science reporting fascinating and innovative discoveries happening all over the world across a wide variety of disciplinary areas. Skim the titles below to catch up on what is happening and to learn what the team at MD Biosciences is reading about. Follow the links to read more about something that catches your eye!
Over the past couple of decades, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have become the number one cause of liver disease in Western countries. Recent data confirm that NAFLD and NASH play an equally important role in the Middle East, Far East, Africa, the Caribbean, and Latin America. The prevalence of NAFLD/NASH continues to increase along with its associated risk factors, including metabolic disorder, obesity, diabetes and hypertension. Therefore, understanding the mechanism of these diseases has become a priority. Recent investigations into the effect of chronic liver inflammation have shed light on the role of both the adaptive and innate immune systems in both NAFLD and NASH. Long suspected to play a part in such metabolic disorders along with nutrition and hormonal imbalances, the immune system has been of great interest to researchers for development of specific drug targets to maximize glucose regulation, minimize inflammatory damage to tissues and prevent the development of fibrosis that can lead to liver failure.
On Thusday, MD Biosciences' Lead Scientist Britnie James, Ph.D. presented at the 2nd Annual Translational Microbiome Conference held in Boston, MA. Her talk entitled "Understanding the Impact of Animal Vendors and the Microbiome in Tumor Progression and Treatment in a Model of Metastatic Breast Cancer" highlights the importance of the role of the micorbiome in disease progression and treatment.
As we wind down to years end, we at MD Biosciences would like to thank everyone, especially our collaborators, for making this year a success. We have undergone significant growth that we expect to continue throughout the upcoming year.
The 12th World Congress on Inflammation wrapped up on Wednesday August 12th after four days packed with cutting edge inflammatory research by key opinions leaders in the field. Presentations hit every aspect of the scientific spectrum from development of pre-clinical models through retrospective studies on new target therapies and everything in between. Highlights of the conference included the Keynote Lecture by Luke O’Neill of Trinity College Dublin, the Symposium “Mechanisms Underlying Microbiome-Mediated Inflammation”, and multiple discussions on identifying and targeting novel biomarkers of inflammatory diseases.
IL-33 is a member of the IL-1 cytokine family that is expressed constitutively in the nucleus of epithelial and endothelial cells as well as in CNS oligodendrocyte and astrocyte cells (1-2). Its release in response to cell damage and/or death has earned it the classification of “alarmin” – an immunological alarm signal that is released in times of cellular distress (3-4). Upon release, IL-33 binds to the T1/ST2 and IL-1R accessory protein (IL-1RAP) heterodimer complex to activate the MYD88-dependant signaling pathway (1).
Studies targeting the function of IL-33 and/or signaling through its T1/ST2 receptor have highlighted the dual role this versatile cytokine pathway plays in the induction inflammatory immune reactions. More interestingly, these reactions can be either beneficial or pathological in nature. Here we will discuss the pathological role of IL-33 in disease.
Rheumatoid arthritis is a chronic and progressive inflammatory condition estimated to affect between 0.5-1% of the world's population, with more women being affected than men. It is a systemic disease manifesting mainly as a disabiling destruction of the synovial joints of the hands and feet.